Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Frontier BiotechnologiesSHSE:688221 -6.45%67 PS Ratio is 18.88 as of Jul. 26, 2026, which is 63% below its 10-year median of 50.92. GuruFocus rates SHSE:688221 with a GF Score™ of 67/100 and a GF Value™ of ¥37.44 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 954 Drug Manufacturers companies, Frontier Biotechnologies ranks worse than 93.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Frontier Biotechnologies's share price is ¥19.86.
Frontier Biotechnologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.05. Hence, Frontier Biotechnologies's PS Ratio for today is 18.88.
Good Sign:
Frontier Biotechnologies Inc stock PS Ratio (=18.88) is close to 1-year low of 17.45.
The historical rank and industry rank for Frontier Biotechnologies's PS Ratio or its related term are showing as below:
SHSE:688221'
s PS Ratio Range Over the Past 10 Years
Min: 14.01 Med: 50.92 Max: 204.63
Current: 18.88
During the past 12 years, Frontier Biotechnologies's highest PS Ratio was 204.63. The lowest was 14.01. And the median was 50.92.
SHSE:688221's PS Ratio is ranked worse than 93.5% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.245
vs SHSE:688221: 18.88
During the past 12 years, Frontier Biotechnologies's highest 3-Year average Revenue per Share Growth Rate was 141.00% per year. The lowest was 12.40% per year. And the median was 44.60% per year.
Back to Basics: PS Ratio
Frontier Biotechnologies (SHSE:688221) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontier Biotechnologies PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Frontier Biotechnologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Frontier Biotechnologies's Share Price of today is ¥19.86. Frontier Biotechnologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Frontier Biotechnologies (SHSE:688221) has a PS Ratio of 18.88 as of Jul. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Frontier Biotechnologies and its competitors. This is 63% below median its historical median of 50.92. Over the past decade, Frontier Biotechnologies' PS Ratio has ranged from 14.01 to 204.63. According to the industry distribution chart, Frontier Biotechnologies ranks #892 out of 954 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Frontier Biotechnologies' PS Ratio too high?
Frontier Biotechnologies' current PS Ratio of 18.88 is 63% below median its 10-year median of 50.92. Over the past 10 years, this metric has ranged from a low of 14.01 to a high of 204.63. The Drug Manufacturers industry median PS Ratio is 2.25. Frontier Biotechnologies' value of 18.88 is 741% above this industry median. Based on the distribution chart, Frontier Biotechnologies ranks #892 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Frontier Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Frontier Biotechnologies ranks #892 out of 954 companies for PS Ratio. This places Frontier Biotechnologies in the lower half of its industry. The industry median PS Ratio is 2.25. Frontier Biotechnologies' value of 18.88 is 741% above this benchmark. Historically, Frontier Biotechnologies' own PS Ratio has ranged from 14.01 to 204.63 over the past decade. While the company's 10-year median is 50.92 vs. the industry median of 2.25, Frontier Biotechnologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.25, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontier Biotechnologies's current PS Ratio of 18.88 is 741% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Frontier Biotechnologies and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontier Biotechnologies's current PS Ratio is 18.88, which is 63% below median its own 10-year median of 50.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥37.44, compared to a current price of ¥19.86 — trading 47% below its estimated fair value. The current PS Ratio is 18.88, which is 63% below median its 10-year median of 50.92 and 741% above the Drug Manufacturers industry median of 2.25. Frontier Biotechnologies' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current PS Ratio is 18.88 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?
Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued.
The current stock price of ¥19.86 is trading 47% below its estimated GF Value™ of ¥37.44.
GuruFocus considers Frontier Biotechnologies to be Significantly Undervalued.
Key valuation signals for SHSE:688221:
PS Ratio: 18.88 (63% below median its 10-year median of 50.92)
GF Value™: ¥37.44 vs. price of ¥19.86 (47% below fair value)
Industry Position: 741% above the Drug Manufacturers median (#892 of 954)
No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688221 has been successfully added to your 
